The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis To the Editor: Quinacrine, a compounded antimalarial, has been used for patients intolerant or unresponsive to hydroxychloroquine. In March 2016, the Pharmacy Compounding Advisory Committee raised safety concerns about quinacrine-associated aplastic anemia. In addition, the Office of New Drugs advised that although quinacrine might be safe at the 100 mg/ day dose prescribed for rheumatic skin diseases, generalists might prescribe this drug at higher doses and for alternative indications that have yet to be formally studied. As a consequence, this orphan drug may no longer be compounded and might become effectively unavailable with a prescription, requiring an Investigational New Drug, institutional review board approval, patient consent, and toxicity reporting. 1 To evaluate the need for continued access, we surveyed providers at various institutions to determine their quinacrine prescribing practices. Two rheumatologic skin disease specialists (Drs Costner and Bangert) from Texas estimated having seen 96 and 30 patients on quinacrine within the last year but Change from baseline Psoriasis Area and Severity Index (PASI) in induction phase (baseline to week 12, pooled data). A repeated-measures, mixed-effects model was used to analyze the percentage change from baseline in the PASI. Symbols without black outlining indicate least-squares means; I-bars, 95% confidence intervals (CIs). Median time to 75%, 50%, and 25% reduction in mean PASI was estimated from bootstrap samples with the use of linear interpolation between time points. Multiple imputation was used to impute missing data with 3 imputed datasets.
could not provide exact figures. An academic dermatologist (Dr Sontheimer) from Utah prescribed quinacrine to 98 patients over a 3-year period. We examine the extent of quinacrine use and its associated toxicities at the Hospital of the University of Pennsylvania (HUP).
Through an electronic search of HUP's data stores from June 1, 2015, through May 31, 2016, we found that out of 899,990 active patients 241 (0.027%) were prescribed quinacrine. Most prescriptions were ordered by dermatology (n ¼ 177) and rheumatology (n ¼ 75), with 18 individuals prescribed by multiple departments. Records from 111 patients who filled prescriptions at the hospital pharmacy indicated that quinacrine was prescribed to 63.1% (n ¼ 70) by dermatologists, 34.2% (n ¼ 38) by rheumatologists, and 2.7% (n ¼ 3) by internists. Although the Office of New Drugs stated that maintaining quinacrine availability would open access to ''any prescriber.for any use.at any dose,'' we found that quinacrine has almost exclusively been prescribed by rheumatic skin disease specialists at our center. (Table I) . 2 Of the quinacrine users, 36 patients started the medication recently and the details of the course were unavailable. Quinacrine was chosen in most (86.1%, n ¼ 241) of the remaining 280 because of hydroxychloroquine refractoriness, consistent with studies on its efficacy for recalcitrant disease. 3 Following initiation, quinacrine was discontinued in 50.4% (n ¼ 141), hydroxychloroquine in 44.5% Table II . Toxicities of quinacrine, hydroxychloroquine, and chloroquine (n ¼ 237), and chloroquine in 62.2% (n ¼ 61). Patients on these medications are not mutually exclusive; most patients were taking either hydroxychloroquine or chloroquine in combination with quinacrine. Quinacrine was discontinued more often than other antimalarials because of the cost and barriers to its access (quinacrine 23.4%, n ¼ 33; hydroxychloroquine 4.6%, n ¼ 11; chloroquine 16.4%, n ¼ 10) rather than because of the side effects (quinacrine 30.5%, n ¼ 43; hydroxychloroquine 42.6%, n ¼ 101; chloroquine 49.2%, n ¼ 30) (Table II) . Following side effects, quinacrine was restarted in 27.7% (n ¼ 13), hydroxychloroquine in 25.7% (n ¼ 26), and chloroquine in 16.7% (n ¼ 5). There were 2 instances of mild transaminitis and 3 of slight hematologic disturbances not clearly attributable to quinacrine. In prior reports of World War II soldiers, 1/500,000 patients experienced aplastic anemia at dosages exceeding 100 mg/day. 4, 5 Quinacrine safety is thus supported by evidence from this large cohort.
Our study is limited by its retrospective methodology. It is crucial to continue to examine the repercussions of the loss of quinacrine availability considering the lack of suitable alternatives. 3, 4 The authors also determined whether products that included tanning or bronzing on their primary display panel were less likely to meet these recommendations. In their study, Yazdani and colleagues found that only 34.5% of sunscreens sold at the largest US retailer and 41.0% of sunscreens sold at the largest US pharmacy retailer met all AAD recommendations. In addition, tanning and bronzing products were significantly less likely to meet AAD recommendations.
We conducted a follow-up to this study in January 2017 to determine if a greater percentage of sunscreens and tanning and bronzing products now meet AAD guidelines. The websites of both Walmart and Walgreens were visited on January 25, 2017, and the study methods as detailed by Yazdani et al were replicated as follows: Walmart[''pharmacy, health & beauty'' [ ''skin care'' [ ''sun care''; Walgreens
